Metotrexato Semanal Wyeth (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for synthesizing tetrahydrofolate, a co‑factor for DNA production. By limiting DNA synthesis, it suppresses the proliferation of immune cells and decreases cytokine release, providing anti‑inflammatory and immunosuppressive effects that are useful in autoimmune diseases.

The exact dose of Metotrexato Semanal Wyeth is determined by the prescribing clinician based on the patient’s condition, weight, renal function and response to therapy. Healthcare professionals tailor the weekly dosage to achieve optimal therapeutic benefit while minimizing potential toxicity.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant. Effective contraception is required for both men and women during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methotrexate is an antimetabolite that offers oral weekly dosing, which can be more convenient than biologic agents that require subcutaneous or intravenous administration. While biologics target specific cytokines, methotrexate provides broad immunosuppression and is often used as first‑line therapy or in combination with other agents for synergistic effect.

Store Metotrexato Semanal Wyeth below 25 °C in its original container, protecting it from moisture, heat and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Metotrexato Semanal Wyeth is taken orally, typically as a single weekly dose. Patients should follow the prescribing clinician’s instructions regarding timing (e.g., with or without food) and any required folic acid supplementation to reduce gastrointestinal side effects.

The most serious risks include severe liver toxicity, bone marrow suppression leading to anemia or infection, and pulmonary toxicity such as interstitial pneumonitis. Early detection through regular laboratory monitoring and prompt reporting of symptoms like persistent cough, jaundice or unusual bruising are essential for safety.

Methotrexate should not be used by individuals who are pregnant, planning pregnancy, or breastfeeding. It is also contraindicated in patients with severe liver disease, significant renal impairment, uncontrolled infections, or known hypersensitivity to methotrexate or any of its excipients.